Checkpoint inhibitor–associated pneumonitis (CIP) is a serious manifestation following tumor immunotherapy, typically mediated by T lymphocytes. However, the heterogeneity in blood inflammatory profiles and its implications on clinical characteristics and… Click to show full abstract
Checkpoint inhibitor–associated pneumonitis (CIP) is a serious manifestation following tumor immunotherapy, typically mediated by T lymphocytes. However, the heterogeneity in blood inflammatory profiles and its implications on clinical characteristics and outcomes for CIP remain underexplored.
Keywords:
inhibitor associated;
checkpoint inhibitor;
associated pneumonitis
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!